IC-8 Apthera IOL New Enrollment Post Approval Study

NCT06060041 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 435

Last updated 2026-01-12

No results posted yet for this study

Summary

The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

Conditions

  • Cataract
  • Presbyopia
  • Posterior Capsule Opacification

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-08
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060041 on ClinicalTrials.gov